NKTR stock

This is a good one for my MT brethren to keep an eye on. Had really good data come from its phase 2b study on a new treatment to treat eczema. Stock went through the roof yesterday and a lot of analysts have put it as a strong buy with projections of the stock hitting $60+

quote:

---

Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for treating moderate-to-severe atopic dermatitis (eczema), marking a pivotal moment for the cash-strapped biotech company. The study met both primary and secondary endpoints, validating the company's novel regulatory T-cell approach to treating inflammatory skin conditions.

---

quote:

---

Atopic dermatitis represents a substantial market opportunity in the United States. Around 31.6 million people (roughly 10% of the population) have some form of eczema, according to the National Eczema Association. More than 30 million Americans live with atopic dermatitis--the skin condition commonly called eczema. While several FDA-approved treatments exist, including biologics like Dupixent, Ebglyss, Adbry, and Nemluvio, significant unmet medical need remains for patients who don’t respond adequately to current therapies or experience side effects.

The REZOLVE-AD Phase 2b study evaluated rezpegaldesleukin in 393 patients with moderate-to-severe atopic dermatitis. The study achieved its primary endpoint with improvements measured by the Eczema Area and Severity Index (EASI) score after a 16-week treatment period. The drug also met key secondary endpoints, including the proportion of patients achieving clear or almost clear skin.

---

LINK

LINK

I snagged a bunch at $19 yesterday. Will probably exit around $40. Up 5% premarket today.